
CapsoVision, Inc
100
Recent developments include Q3 2026 earnings call disclosures, FDA clearance and commercialization of AI Highlights for CapsoCam Plus, and progress in clinical studies and regulatory submissions for CapsoCam Colon and new indications.
- CapsoVision reported a reduction in Q3 2026 net loss and discussed operational updates during its Q3 2026 earnings call [N1][N2][N3].
- The company received FDA clearance for its AI Highlights tool for CapsoCam Plus on September 25, 2026, with U.S. commercialization starting November 2, 2026, and EU commercialization underway [N7][N8].
- CapsoVision is advancing clinical studies for its second generation CapsoCam Colon capsule, enrolling over 500 patients in a pivotal study, with FDA 510(k) submission planned for Q3 2026 [N5].
- The company is pursuing new indications including pancreatic cancer and esophageal varices screening, with feasibility and clinical studies planned subject to funding and regulatory approvals [N5].
CapsoVision, Inc develops and commercializes capsule endoscopy solutions for diagnosing abnormalities in the gastrointestinal tract. Its flagship product, CapsoCam Plus, is a single-use capsule that captures 360° panoramic video of the small bowel mucosa, enabling superior diagnostic yield compared to competitors. The system includes cloud-based and software platforms for remote and local video review. The company has integrated AI-assisted pathology detection technology into CapsoCam Plus, receiving FDA clearance for the AI Highlights tool in 2026. CapsoVision is developing the CapsoCam Colon capsule, designed to visualize the colon and detect polyps using AI and 3D sensing technology. The company is conducting pivotal clinical studies and pursuing FDA 510(k) clearance for this product. CapsoVision's business model includes direct sales in the U.S. and distributor sales internationally. The company faces competition from larger firms with established brands and AI capabilities. It has a portfolio of over 140 patents and invests in R&D to enhance its products and expand indications, including pancreatic cancer and esophageal varices screening. Financially, the company has a history of net losses and substantial doubt about its ability to continue as a going concern, with recent capital raises supporting ongoing operations and clinical programs [S1][S2].
CapsoVision, Inc is a medical technology company specializing in GI tract capsule endoscopy solutions, primarily the CapsoCam Plus for small bowel visualization and the in-development CapsoCam Colon for colon visualization and polyp detection. The company integrates AI technology to enhance diagnostic accuracy and workflow efficiency. Financial disclosures as of September 30, 2026, show net losses with a substantial doubt about going concern, current assets of $31.0 million, current liabilities of $6.1 million, and a current ratio of 5.07. Recent FDA clearances include AI Highlights for CapsoCam Plus, with commercialization underway. The company is advancing clinical studies and regulatory submissions for CapsoCam Colon and exploring new indications such as pancreatic cancer screening. Risks include regulatory delays, competitive pressures, supply chain vulnerabilities, and reimbursement uncertainties [S1][S2][N1][N3][N7][N8]. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
CapsoVision's recent FDA clearance and commercialization of its AI Highlights tool for CapsoCam Plus may improve diagnostic efficiency and provider adoption. The development and anticipated regulatory clearance of the second generation CapsoCam Colon capsule, incorporating AI and enhanced optics, could expand the company's addressable market beyond small bowel indications. The company's efforts to pursue new indications such as pancreatic cancer and esophageal varices screening represent potential avenues for future product expansion. Its strong patent portfolio and ongoing R&D investments support continued innovation. Capital raises in 2026 provide funding for clinical studies and commercialization activities [S1][S2][N7][N8][N5].
CapsoVision faces risks including regulatory delays or failure to obtain FDA 510(k) clearances for its AI technologies and CapsoCam Colon capsule, which could impede commercialization and revenue growth. The company has a history of net losses and substantial doubt about its ability to continue as a going concern, requiring additional financing that may dilute shareholders. Competitive pressures from larger companies with greater resources and brand recognition may limit market penetration. Supply chain dependencies on single-source suppliers in Asia pose operational risks. Reimbursement uncertainties and limited current indications constrain near-term revenue growth. Clinical studies may not yield favorable results or peer-reviewed publications, affecting market acceptance [S2].
CapsoVision's competitive advantages include its proprietary 360° panoramic capsule technology, which provides superior diagnostic coverage compared to end-view systems, and its zero-capex, wire-free data collection model that enhances clinical workflow and patient experience. The integration of AI-assisted pathology detection and proprietary 3D sensing technology for polyp measurement further differentiates its products. The company holds a substantial intellectual property portfolio with over 140 issued patents covering multiple aspects of its capsules and technology. Its cloud-based platform enables remote data access and telemedicine capabilities, supporting scalability and convenience. These factors collectively create barriers to entry and support differentiation in the capsule endoscopy market [S1].
• Regulatory Approval Risks: Delays or failure to obtain FDA 510(k) clearances for AI-assisted technologies and CapsoCam Colon capsule could adversely impact commercialization and revenue.
• Financial and Going Concern Risks: The company has a history of net losses, substantial doubt about going concern, and will likely need additional financing, which may dilute existing shareholders.
• Competitive Risks: Competition from larger, better-resourced companies with established brands and AI capabilities may limit market share and growth.
• Supply Chain Risks: Dependence on single-source suppliers in Asia, particularly Taiwan and Japan, exposes the company to geopolitical, trade, and natural disaster risks affecting production.
• Reimbursement Risks: Inadequate reimbursement rates from Medicare and third-party payors could hinder product commercialization and adoption.
• Clinical and Market Acceptance Risks: Clinical studies may not demonstrate required performance; AI Highlights and new products may not achieve expected market acceptance among providers and patients.
Business trends: Continued integration of AI technology into capsule endoscopy products, expansion into colon and new GI indications, and increasing telemedicine adoption.
Execution milestones: FDA clearance and commercialization of AI Highlights tool, pivotal clinical studies and FDA 510(k) submission for second generation CapsoCam Colon, and development of complementary devices.
Key risks: Regulatory approval delays or failures, financial sustainability concerns including going concern doubts, competitive pressures, supply chain vulnerabilities, and reimbursement uncertainties.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- CapsoVision, Inc is a global commercial-stage medical technology company focused on diagnostic and screening products for abnormalities of the gastrointestinal (GI) tract, headquartered in Saratoga, California, incorporated in 2005 [S1].
- The company's core product is the CapsoCam capsule endoscopy solution, including the CapsoCam Plus capsule and associated software CapsoCloud and CapsoView [S1].
- CapsoCam Plus is a single-use, FDA-cleared Class II device for visualizing the small bowel mucosa in adults and children aged 2 years and above, with over 161,000 patients treated as of December 31, 2025 [S1].
- Revenue from CapsoCam Plus was approximately $13.6 million in 2025, up 15% from $11.8 million in 2024, with growth driven by increased capsule sales [S1].
- CapsoCam Plus captures a 360° panoramic video using four cameras, providing superior diagnostic yield compared to competitors with end-view systems [S1].
- The CapsoCam Plus system is a zero-capex, wire-free data collection solution storing video onboard, with cloud-based remote access (CapsoCloud) in the U.S. and software-based review (CapsoView) outside the U.S. [S1].
- In December 2024, FDA clearance was obtained for pediatric use (children aged 2+) and telemedicine supervision allowing remote ingestion of the capsule [S1].
- CapsoVision is developing AI-assisted pathology detection technology integrated into CapsoCam Plus, with FDA 510(k) submission made in December 2025 and FDA clearance received for AI Highlights™ on September 25, 2026; commercialization began in the U.S. November 2, 2026, and in the EU [S1][S2][N7][N8].
- The company is developing a capsule delivery device and a patency capsule, with FDA 510(k) submission for the patency capsule planned for early 2027 [S1][S2].
- CapsoVision is developing the CapsoCam Colon capsule endoscopy system for colon visualization and polyp detection, incorporating AI for automated polyp detection and proprietary 3D sensing technology for polyp size measurement [S1].
- The first generation CapsoCam Colon 510(k) submission was discontinued after FDA feedback; focus shifted to a second generation with improved optics and AI, with a pivotal study enrolling over 500 patients and 510(k) submission planned for Q3 2026 [S1].
- CapsoCam Colon is intended for patients with incomplete colonoscopy or GI bleeding risks; broader indications and market expansion depend on regulatory approvals and clinical performance [S1].
- CapsoVision holds over 140 issued patents covering capsule and technology aspects as of December 31, 2025 [S1].
- The company has incurred net losses since inception, with a net loss of $7.3 million for Q3 2026 and accumulated deficit of $177.5 million as of September 30, 2026 [S2].
- Liquidity as of September 30, 2026 includes current assets of $31.0 million and current liabilities of $6.1 million, yielding a current ratio of 5.07 [S2].
- The company raised $14 million in a private placement in March 2026, $18 million in a registered direct offering in Q3 2026, and $1.8 million under an ATM program, but substantial doubt about going concern remains [S2].
- Revenue growth depends currently on CapsoCam Plus sales; CapsoCam Colon-related revenues are not expected until after FDA clearance, anticipated in the second half of 2027 [S2].
- Risks include regulatory delays or failure to obtain FDA 510(k) clearances for AI technology and CapsoCam Colon, competitive pressures from larger companies, supply chain risks especially in Asia, and reimbursement uncertainties [S2].
- Clinical studies for CapsoCam Colon and other pipeline products may not yield required performance data or peer-reviewed publications [S2].
- The company is pursuing new indications including pancreatic cancer and esophageal varices screening, with feasibility and clinical studies planned subject to funding [S1][N5].
- Recent news includes Q3 2026 earnings call transcripts and reports of Q3 loss reduction, FDA clearance of AI Highlights tool, and mapping of AI capsule use into colon and pancreatic cancer screening [N1][N2][N3][N5][N7][N8].
Generated 2026-11-15
- S1 | 2026-03-26 | 10-K
- S2 | 2026-11-12 | 10-Q
- N1 | 2026-11-13 | www.nasdaq.com | CapsoVision (CV) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/capsovision-cv-q3-2026-earnings-call-transcript
- N2 | 2026-11-12 | www.nasdaq.com | What CapsoVision (CV) Said on Its Q3 Earnings Call | https://www.nasdaq.com/articles/what-capsovision-cv-said-its-q3-earnings-call
- N3 | 2026-11-12 | www.nasdaq.com | CapsoVision, Inc Q3 Loss Drops | https://www.nasdaq.com/articles/capsovision-inc-q3-loss-drops
- N4 | 2026-11-05 | www.nasdaq.com | 10x Genomics (TXG) Reports Q3 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/10x-genomics-txg-reports-q3-loss-beats-revenue-estimates
- N5 | 2026-10-24 | www.nasdaq.com | CapsoVision Maps AI Capsule Push Into Colon, Pancreatic Cancer Screening | https://www.nasdaq.com/articles/capsovision-maps-ai-capsule-push-colon-pancreatic-cancer-screening
- N6 | 2026-10-02 | www.nasdaq.com | Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data | https://www.nasdaq.com/articles/weekly-buzz-ew-abbv-mirm-score-fda-wins-azn-nvo-strike-deals-lly-kod-report-data
- N7 | 2026-09-28 | www.nasdaq.com | CapsoVision's AI Highlights Receives FDA Clearance For CapsoCam Plus | https://www.nasdaq.com/articles/capsovisions-ai-highlights-receives-fda-clearance-capsocam-plus
- N8 | 2026-09-28 | www.nasdaq.com | CapsoVision Wins FDA Clearance For AI Highlights Tool | https://www.nasdaq.com/articles/capsovision-wins-fda-clearance-ai-highlights-tool
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


